|
Background
|
The ABL1 protooncogene encodes a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. The t(9;22) translocation results in the head-to-tail fusion of the BCR (MIM:151410) and ABL1 genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for ABL1. The ABL1 gene is expressed as either a 6- or 7-kb mRNA transcript, with alternatively spliced first exons spliced to the common exons 2-11. Transcript Variant: Transcript variant b includes exon 1b, but not exon 1a, resulting in a different N-terminus. This variant contains an N-terminal glycine which could be myristylated and is thus postulated to be directed to the plasma membrane.
|
Background
References
|
- Saglio, G., et al., Cell. Mol. Life Sci. 61(23):2897-2911 (2004).
- Deming, P.B., et al., Mol. Cell. Biol. 24(23):10289-10299 (2004).
- Graux, C., et al., Nat. Genet. 36(10):1084-1089 (2004).
- Monma, F., et al., Int. J. Hematol. 80(2):155-158 (2004).
- Gustafson, W.C., et al., J. Biol. Chem. 279(10):9400-9408 (2004).
|
Order Information
List Price (USA): $235.00/0.1mg
Related Products
Data Rewards Program
